ReviewFuture microbiology2006
Prospects for the treatment of drug-resistant malaria parasites.
Review in Future microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Ultrasonic-Assisted Fabrication of MIL-100(Fe) Metal-Organic Frameworks as a Carrier for the Controlled Delivery of the Chloroquine Drug.ACS omega · 2023Article
- Synthesis of five- and six-membered cyclic organic peroxides: Key transformations into peroxide ring-retaining products.Beilstein journal of organic chemistry · 2014Review
- Cryo transmission X-ray imaging of the malaria parasite, P. falciparum.Journal of structural biology · 2011Article
- Compounds structurally related to ellagic acid show improved antiplasmodial activity.Antimicrobial agents and chemotherapy · 2009Article
- The protein-phosphatome of the human malaria parasite Plasmodium falciparum.BMC genomics · 2008Article
- Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology.Antimicrobial agents and chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Widespread parasitic resistance has led to an urgent need for the development and implementation of new drugs for the treatment of Plasmodium falciparum malaria. Artemisinin and its derivatives are becoming increasingly important, used preferably in combination with a second antimalarial agent to increase the efficacy and slow the development of resistance. However, cost, production and pharmacological issues associated with artemisinin derivatives and potential partner drugs are hindering the implementation of combination therapies. This article reviews the molecular basis of the action of, and resistance to, different antimalarials and examines the prospects for the next generation of drugs to combat this potentially lethal human pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.